Disposition of 18674 shares by Coleen Glessner of Emergent Biosolutions at 9.01 subject to Rule 16b-3
| EBS Stock | USD 5.80 0.59 9.23% |
Slightly above 61% of Emergent Biosolutions' investor base is looking to short. The analysis of the overall investor sentiment regarding Emergent Biosolutions suggests that many traders are alarmed. Emergent Biosolutions' investing sentiment can be driven by a variety of factors including economic data, Emergent Biosolutions' earnings reports, geopolitical events, and overall market trends.
Emergent |
Filed transaction by Emergent Biosolutions Officer: Evp, Quality & Ethics, And Cpl. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Emergent Biosolutions Fundamental Analysis
We analyze Emergent Biosolutions' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emergent Biosolutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emergent Biosolutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Emergent Biosolutions is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Emergent Biosolutions Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Emergent Biosolutions stock to make a market-neutral strategy. Peer analysis of Emergent Biosolutions could also be used in its relative valuation, which is a method of valuing Emergent Biosolutions by comparing valuation metrics with similar companies.
Peers
Emergent Biosolutions Related Equities
| COLL | Collegium Pharmaceutical | 4.67 | ||||
| LFCR | Lifecore Biomedical | 3.71 | ||||
| AKAN | Akanda Corp | 3.12 | ||||
| BHC | Bausch Health | 2.00 | ||||
| PBH | Prestige Brand | 1.48 | ||||
| ITCI | Intracellular | 0.05 | ||||
| NBIX | Neurocrine Biosciences | 1.05 | ||||
| ZTS | Zoetis | 1.71 | ||||
| ALKS | Alkermes Plc | 1.79 | ||||
| CPIX | Cumberland Pharmaceuticals | 2.36 | ||||
| DRRX | Durect | 2.53 |
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.